These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26878560)

  • 1. Effectiveness and safety of liraglutide after three years of treatment.
    Ponzani P; Scardapane M; Nicolucci A; Rossi MC
    Minerva Endocrinol; 2016 Mar; 41(1):35-42. PubMed ID: 26878560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effectiveness and safety of liraglutide in clinical practice.
    Ponzani P
    Minerva Endocrinol; 2013 Mar; 38(1):103-12. PubMed ID: 23435446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function.
    Rondinelli M; Rossi A; Gandolfi A; Saponaro F; Bucciarelli L; Adda G; Molinari C; Montefusco L; Specchia C; Chiara Rossi M; Scardapane M; Arosio M; Genovese S
    Clin Ther; 2017 Jan; 39(1):159-169. PubMed ID: 27939305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liraglutide Improves Glycemic and Blood Pressure Control and Ameliorates Progression of Left Ventricular Hypertrophy in Patients with Type 2 Diabetes Mellitus on Peritoneal Dialysis.
    Hiramatsu T; Ozeki A; Asai K; Saka M; Hobo A; Furuta S
    Ther Apher Dial; 2015 Dec; 19(6):598-605. PubMed ID: 26556397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ROOTS: A multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza®) in type 2 diabetic patients.
    Buysschaert M; D'Hooge D; Preumont V;
    Diabetes Metab Syndr; 2015; 9(3):139-42. PubMed ID: 26004030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort.
    Mirani M; Favacchio G; Serone E; Lucisano G; Rossi MC; Berra CC
    Pharmacol Res; 2018 Nov; 137():270-279. PubMed ID: 30213563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes.
    Wijkman MO; Dena M; Dahlqvist S; Sofizadeh S; Hirsch I; Tuomilehto J; Mårtensson J; Torffvit O; Imberg H; Saeed A; Lind M
    J Clin Hypertens (Greenwich); 2019 Jan; 21(1):105-115. PubMed ID: 30515978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain.
    Gomez-Peralta F; Lecube A; Fernández-Mariño A; Alonso Troncoso I; Morales C; Morales-Pérez FM; Guler I; Cadarso-Suárez C
    Diabet Med; 2018 Nov; 35(11):1605-1612. PubMed ID: 29943854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of age and metformin treatment status on reported gastrointestinal side effects with liraglutide treatment in type 2 diabetes.
    Thong KY; Gupta PS; Blann AD; Ryder RE
    Diabetes Res Clin Pract; 2015 Jul; 109(1):124-9. PubMed ID: 25937541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients.
    Russo GT; Labate AM; Giandalia A; Romeo EL; Villari P; Alibrandi A; Perdichizzi G; Cucinotta D
    J Endocrinol Invest; 2015 Jan; 38(1):81-9. PubMed ID: 25173876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients.
    Fadini GP; Simioni N; Frison V; Dal Pos M; Bettio M; Rocchini P; Avogaro A
    Acta Diabetol; 2013 Dec; 50(6):943-9. PubMed ID: 23754673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial.
    Kajiwara M; Tanaka A; Kawasaki T; Nakao K; Sakamoto T; Toyoda S; Inoue T; Koga N; Node K
    J Cardiol; 2017 Mar; 69(3):511-517. PubMed ID: 27894787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of insulin detemir in combination with oral antidiabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study.
    Caputo S; Maran A; Mannino D; Morano S; Lastoria G; Nicoziani P
    Minerva Endocrinol; 2015 Dec; 40(4):249-58. PubMed ID: 26551483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
    Vedtofte L; Knop FK; Vilsbøll T
    Expert Rev Clin Pharmacol; 2015 May; 8(3):273-82. PubMed ID: 25816888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes.
    Mirabelli M; Chiefari E; Caroleo P; Arcidiacono B; Corigliano DM; Giuliano S; Brunetti FS; Tanyolaç S; Foti DP; Puccio L; Brunetti A
    Int J Environ Res Public Health; 2019 Dec; 17(1):. PubMed ID: 31892206
    [No Abstract]   [Full Text] [Related]  

  • 17. Exposure-response analyses of liraglutide 3.0 mg for weight management.
    Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
    Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.
    Faber R; Zander M; Pena A; Michelsen MM; Mygind ND; Prescott E
    Cardiovasc Diabetol; 2015 Apr; 14():41. PubMed ID: 25896352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study.
    Osonoi T; Saito M; Tamasawa A; Ishida H; Tsujino D; Nishimura R; Utsunomiya K
    PLoS One; 2014; 9(12):e113468. PubMed ID: 25526642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Persistence of Liraglutide Treatment Among Patients with Type 2 Diabetes Treated in Primary Care and Specialist Settings: A Subgroup Analysis from the EVIDENCE Study, a Prospective, 2-Year Follow-up, Observational, Post-Marketing Study.
    Martinez L; Penfornis A; Gautier JF; Eschwège E; Charpentier G; Bouzidi A; Gourdy P
    Adv Ther; 2017 Mar; 34(3):674-685. PubMed ID: 28138803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.